Brentuximab vedotin for relapse or progression therapy after allogeneic hematopoietic stem cell transplantation in relapsed / refractory classic Hodgkin lymphoma

被引：0
|
作者：
Mikhailova, N. [1 ]
Popova, M. [1 ]
Kondakova, E. [1 ]
Ivanova, M. [1 ]
Borzenkova, E. [1 ]
Alaynskiy, A. [1 ]
Bondarenko, S. [1 ]
Afanasyev, B. [1 ]
Babenko, E. [1 ]
机构：
[1] First St Petersburg Pavlov State Med Univ, St Petersburg, Russia
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P728
引用
收藏
页码：S503 / S503
页数：1
相关论文
共 50 条
  • [21] A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation
    Tacyildiz, Nurdan
    Tanyildiz, Hikmet Gulsah
    Unal, Emel
    Dincaslan, Handan
    Asarcikli, Fikret
    Aksoy, Basak Adakli
    Vatansever, Goksel
    Yavuz, Gulsan
    TURKISH JOURNAL OF PEDIATRICS, 2019, 61 (05) : 671 - 676
  • [22] A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
    Perales, Miguel -Angel
    Cho, Christina
    Eaton, Anne
    Moskowitz, Alison J.
    Nguyen, Victoria
    Conzales-Dadiz, Anne Marie R.
    Devlin, Sean
    Giralt, Sergio A.
    Jakubowski, Ann A.
    Matasar, Matthew J.
    Noy, Ariela
    Portlock, Carol S.
    Straus, David J.
    Young, James W.
    Barker, Juliet N.
    Moskowitz, Craig H.
    BLOOD, 2015, 126 (23)
  • [23] Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
    Bazarbachi, Ali
    Boumendil, Ariane
    Finel, Herve
    Mohty, Mohamad
    Castagna, Luca
    Blaise, Didier
    Peggs, Karl S.
    Afanasyev, Boris
    Diez-Martin, J. L.
    Corradini, Paolo
    Michonneau, David
    Robinson, Stephen
    Gutierrez Garcia, Gonzalo
    Bonifazi, Francesca
    Yakoub-Agha, Ibrahim
    Gulbas, Zafer
    Bloor, Adrian
    Delage, Jeremy
    Esquirol, Albert
    Malladi, Ram
    Scheid, Christof
    El-Cheikh, Jean
    Ghesquieres, Herve
    Montoto, Silvia
    Dreger, Peter
    Sureda, Anna
    CANCER, 2019, 125 (01) : 90 - 98
  • [24] Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
    Garciaz, Sylvain
    Coso, Diane
    Peyrade, Frederic
    Fuerst, Sabine
    Duran, Segolene
    Chetaille, Bruno
    Brenot-Rossi, Isabelle
    Devillier, Raynier
    Granata, Angela
    Blaise, Didier
    Bouabdallah, Reda
    HEMATOLOGICAL ONCOLOGY, 2014, 32 (04) : 187 - 191
  • [25] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [26] Improving Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in Brentuximab Vedotin Era
    Bachanova, Veronika
    Hegerova, Livia
    Cao, Qing
    Lazaryan, Aleksandr
    McClune, Brian Lee
    Weisdorf, Daniel J.
    Brunstein, Claudio G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S216 - S216
  • [27] Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma
    Armand, Philippe
    Zinzani, Pier Luigi
    Collins, Graham P.
    Cohen, Jonathon B.
    Halwani, Ahmad S.
    Carlo-Stella, Carmelo
    Millenson, Michael M.
    Provencio, Mariano
    Domenech, Eva Domingo
    Roth, Lisa Giulino
    Castagna, Luca
    Kato, Kazunobu
    McKiver, Mihaela Popa
    Sumbul, Anne
    Zhu, Lili
    Santoro, Armando
    BLOOD, 2016, 128 (22)
  • [28] Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma
    Kort, Jeries
    Chidiac, Amanda
    El Sayed, Rola
    Massoud, Radwan
    Nehme, Rita
    Bazarbachi, Ali
    El-Cheikh, Jean
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1732 - 1735
  • [29] Nivolumab salvage therapy before and after allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma
    Cheikh, J. E. I.
    Massoud, R.
    Abudalle, I.
    Haffar, B.
    Mahfouz, R.
    Kharfan-Dabaja, M. A.
    Jisr, T.
    Mougharbel, A.
    Ibrahim, A.
    Bazarbachi, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S29 - S30
  • [30] Case of successful treatment of Hodgkin lymphoma progression after allogeneic haploidentical stem cell transplantation with combination of brentuximab vedotin therapy and donor lymphocyte infusions
    Motorin, Dmitry
    Zammoeva, Darina
    Badaev, Renat
    Babenetskaya, Diana
    Ilyina, Natalia
    Alexeeva, Yulia
    Zaritskey, Andrey
    BONE MARROW TRANSPLANTATION, 2018, 53 : 603 - 604
12345